Everest Medicines Limited (HKG:1952)
39.54
-0.44 (-1.10%)
Apr 17, 2026, 2:15 PM HKT
Everest Medicines Revenue
In the year 2025, Everest Medicines had annual revenue of 1.71B CNY with 141.51% growth. Everest Medicines had revenue of 1.26B in the half year ending December 31, 2025, with 977.06% growth.
Revenue
1.71B CNY
Revenue Growth
+141.51%
P/S Ratio
7.40
Revenue / Employee
2.36M CNY
Employees
722
Market Cap
14.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.71B | 1.00B | 141.51% |
| Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
| Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
| Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
| Dec 31, 2021 | 54.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 3.58B |
| Shanghai Haohai Biological Technology | 2.72B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Ascentage Pharma Group International | 638.89M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Nanjing Leads Biolabs | 197.25M |
Everest Medicines News
- 8 days ago - China biotech flow picks up as Everest seals US$250 million deal - South China Morning Post
- 2 months ago - Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval - Benzinga
- 1 year ago - AI-powered Cancer Vaccine In The Works - Benzinga
- 1 year ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga